Fig. 4.
AVN-C decrease viability of MDA-MB-231 breast cancer cells in a time and concentration dependent manner. a AVN-C treatment, 48 h. b AVN-C treatment, 72 h. c AVN-C treatment, 96 h. Averages of a biological replicate done in triplicate; * indicates statistical significance difference from 0.4% DMSO negative control as determined by a t test at p < 0.05 level of significance, ** indicates significance level at p < 0.01, *** indicates significance at p < 0.001 level